Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 17/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1693295 | 0.89 | ESRRA (0.51) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1693521 | 0.88 | ESRRA (0.52) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1693168 | 0.87 | ESRRA (0.53) | ESRRAPTGER4GPR183KCNH2 | |
| SCHEMBL1692611 | 0.87 | ESRRA (0.62) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1692784 | 0.87 | ESRRA (0.51) | ESRRAPTGER4GPR183 | |
| SCHEMBL1693439 | 0.85 | ESRRA (0.47) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1692622 | 0.85 | ESRRA (0.49) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1692605 | 0.83 | ESRRA (0.48) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL1693414 | 0.83 | ESRRA (0.46) | ESRRAPTGER4GPR183NR1H2NR1H3 | |
| SCHEMBL12067309 | 0.81 | ESRRA (0.66) | ESRRAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| WO-2011149841-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | ESRRA 3/4885PTGER4 548/4885GPR183 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.